Kunena :: Тема: Posted by Emory Bloomon 28.11.2016 17:19:53: tarceva copay card (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Emory Bloomon 28.11.2016 17:19:53: tarceva copay card

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Emory Bloomon 28.11.2016 17:19:53: tarceva copay card

Страница:
1
2

ТЕМА: Posted by Emory Bloomon 28.11.2016 17:19:53: tarceva copay card

Posted by Emory Bloomon 28.11.2016 17:19:53: tarceva copay card 7 года 5 мес. назад #898

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol . 2013 Apr 10. 31(11):1415-21. [Medline].
The experimental drug Tarceva extended survival in lung-cancer patients, a potential boost for a new class of cancer drugs that take specific aim at tumor cells.
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Tarceva (Erlotinib) where reactions include vomiting. The selected reports were submitted to the FDA during the sample period of about a year.
din-almaty.gov.kz/index.php?option=com_k...7&Itemid=719&lang=ru
So does this mean that you might consider the combo for a never-smoker, female, stage IV. with EGFR mutation? Stable for one year on Tarceva alone? I am not clear on what the risk factors are, other than the general ones for Cox2 inhibitors.
I. To determine the distribution of progression-free survival (PFS) in patients with previously untreated advanced adenocarcinoma of the lung who are never or light former smokers treated with either OSI-774 (erlotinib) (erlotinib hydrochloride) alone (arm A) or in combination with carboplatin/paclitaxel (arm

.
bezpeka.okht.net/index.php/forum/dobro-p...-tarceva-vs-keytruda
For additional Important Safety Information, please see full Prescribing Information at www.tarceva.com .
Réf : Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epithelial growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44
Improving PFS of patients with EGFR -mutant NSCLC treated with erlotinib remains a critical therapeutic challenge. Our study suggests that this is unlikely to be achieved by adding chemotherapy to erlotinib. Current studies are evaluating the benefit of the addition of bevacizumab to erlotinib in EGFR -mutant NSCLC based on a subset analysis of a prior clinical trial. 27 Additional efforts aimed at understanding the biology of EGFR -mutant NSCLC and/or the development of more effective EGFR-targeted therapies are necessary to improve the outcome of patients with EGFR -mutant NSCLC. 28 ,29
www.energoizdelye.ru/forum/28/66014-post...4-tarceva-sales-2013
Tarceva 100mg - 30 Comprimidos na 4Bio Medicamentos Especiais
ERLOTINIB (chlorhydrate) 150 mg cp (TARCEVA) Mise à jour. 23 Février 2016
dibor.com.ua/index.php/forum/post
Secondarily, this study aims to investigate the relationship between erlotinib AUC and rash severity and to evaluate the efficacy of doxycycline in rash management. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
www.teahour.ru/forum/2--/7851-posted-by-...va-radiation-therapy
After a 4-week run-in period (gemcitabine 1000 mg m −2 once weekly plus erlotinib 100 mg per day), patients with metastatic pancreatic cancer who developed grade 0 / 1 rash were randomised to receive gemcitabine plus erlotinib dose escalation (150 mg, increasing by 50 mg every 2 weeks (maximum 250 mg); n = 71) or gemcitabine plus standard-dose erlotinib (100 mg per day; n = 75). The primary end point was to determine whether overall survival (OS) was improved by increasing the erlotinib dose. Secondary end points included progression-free survival (PFS), incidence of grade 2 rash, and safety.
13 Nogueira-Rodrigues A. Carmo CC. Viegas C. et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res. 2008 ; 14. 6324 - 6329.
The study involved two observational cohorts of NSCLC second- or third-line treated patients. In the first, patients received IV chemotherapy alone (233 patients), while patients in the second cohort, received oral erlotinib (166 patients). Only direct costs were taken into account. The analysis adopted the payer’s perspective.
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
www.nixin.su/forum/turniry/663-posted-by...ceva-approval-europe
Tarceva and radiation
Patients treated with Tarceva did not suffer as severe side effects as those treated with chemotherapy.
inktec.by/forum/sublimatsionnye/516-post...22-cost-of-erlotinib
SCHEDA – Erlotinib
Because many solid tumours over express EGFR, Tarceva has therapeutic potential in the treatment of cancers other than just NSCLC.
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
tarceva et resultats ? mOn pere a eu une 1ere chimio qui n'a pas donne de resultat puis un protocole de taxol qu'il n'a pas. Par ptitfleur le 13/08/2007 - 21h39
L’impiego di Erlotinib ( Tarceva ) dopo fallimento di Gefitinib ( Iressa ) nei pazienti con tumore polmonare non a piccole cellule non è stato ben definito nella pratica clinica. Ricercatori giapponesi hanno compiuto un’analisi della letteratura con l’obiettivo di meglio comprendere l’efficacia di Erlotinib dopo fallimento della terapia con Gefitinib.